<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04943094</url>
  </required_header>
  <id_info>
    <org_study_id>URODYN</org_study_id>
    <nct_id>NCT04943094</nct_id>
  </id_info>
  <brief_title>Clinical and Functional Consequences of Photodynamic Diagnosis (PDD) and Intravesical Instillation Therapy</brief_title>
  <acronym>URODYN</acronym>
  <official_title>Clinical and Functional Consequences of Photodynamic Diagnosis (PDD) and Intravesical Instillation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aarhus University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim is to evaluate and compare treatment strategies for non-muscle invasive bladder&#xD;
      cancer. Furthermore, the impact of intravesical instillations on bladder function will be&#xD;
      examined by urodynamic examination both prior to and following instillation therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Change in urodynamic specifics (bladder compliance, detrusor overactivity, maximal cystometric capacity)</measure>
    <time_frame>examined at time 0 and after six months</time_frame>
    <description>Obtained from the urodynamic test</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Non-muscle Invasive Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>TURBT alone</arm_group_label>
    <description>Patients treated with TURBT without adjuvant instillation therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TURBT and mitomycin C</arm_group_label>
    <description>Patients treated with TURBT followed by six adjuvant instillations with mitomycin C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TURBT and bacillus Calmette-Guerin</arm_group_label>
    <description>Patients treated with TURBT followed by six adjuvant instillations with BCG</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Urodynamic examination</intervention_name>
    <description>A urodynamic examination is performed in all patients four to six weeks following TURBT and repeated six months later in order to obtain bladder function and possible changes.</description>
    <arm_group_label>TURBT alone</arm_group_label>
    <arm_group_label>TURBT and bacillus Calmette-Guerin</arm_group_label>
    <arm_group_label>TURBT and mitomycin C</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with primary non-muscle invasive bladder cancer or who are diagnosed&#xD;
        with their first or second recurrence.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  non-muscle invasive bladder tumour&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  more than one previous bladder tumour recurrence&#xD;
&#xD;
          -  muscle invasive bladder cancer (at baseline or prior to inclusion)&#xD;
&#xD;
          -  utilization of urinary catheter&#xD;
&#xD;
          -  have had heart valve replacement performed&#xD;
&#xD;
          -  pregnant or lactating&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jørgen B. Jensen, DMSc, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Aarhus Universitetshospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Linea Blichert-Refsgaard, MD</last_name>
    <phone>004530915431</phone>
    <email>lineblic@rm.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jørgen Bjerggaard Jensen, MD</last_name>
      <phone>+45 30915682</phone>
      <email>bjerggaard@clin.au.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 18, 2021</study_first_submitted>
  <study_first_submitted_qc>June 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2021</study_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital</investigator_affiliation>
    <investigator_full_name>Jørgen Bjerggaard Jensen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

